FBXO31: A Potential Drug Target and Biomarker (G79791)

Target Name: FBXO31

NCBI ID: G79791

FBXO31

FBXO31: A Potential Drug Target and Biomarker

F-box proteins are a family of proteins that play a crucial role in various cellular processes. These proteins are involved in cell division, DNA repair, and intracellular signaling, among other things. FBXO31, also known as F-box protein 31, is a member of the F-box protein family and has been identified as a potential drug target or biomarker.

FBXO31 Structure and Function

FBXO31 is a 21-kDa protein that contains 21 amino acid residues. It has a unique structure that consists of a 206 amino acid long N-terminal domain, a 36 amino acid long middle domain, and a 44 amino acid long C-terminal domain. The N-terminal domain contains a unique farnesylated cysteine residue, which is a hallmark of the F-box protein family. The middle domain contains a unique GXXG repeat and a conserved amino acid sequence that is commonly found in the F-box protein family. The C-terminal domain contains a unique GXXC repeat and a conserved amino acid sequence that is also found in the F-box protein family.

FBXO31 is involved in various cellular processes, including cell division, DNA repair, and intracellular signaling. One of the most significant functions of FBXO31 is its role in cell division. FBXO31 is involved in the metaphase stage of cell division and helps to ensure that the sister chromatids align correctly during the anaphase stage. In addition, FBXO31 is also involved in the regulation of DNA repair. When DNA damage occurs, FBXO31 helps to ensure that repair mechanisms are activated and that the repair process is efficient.

FBXO31 is also involved in intracellular signaling. It has been shown to play a role in the regulation of various cellular signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer.

Drug Targeting and Biomarker Potential

FBXO31 has been identified as a potential drug target due to its unique structure and function. The farnesylated cysteine residue in the N-terminal domain of FBXO31 makes it a potential target for small molecules that can modulate the activity of the F-box protein. In addition, the conserved amino acid sequences in the middle and C-terminal domains of FBXO31 make it a potential target for antibodies or other therapeutic agents that can interact with these domains.

FBXO31 has also been identified as a potential biomarker for certain diseases. For example, FBXO31 has been shown to be downregulated in various diseases, including cancer. This suggests that it may be a useful biomarker for the diagnosis and treatment of these diseases. In addition, the regulation of FBXO31 has also been shown to be involved in the development and progression of various diseases, including cancer. This suggests that it may be a useful biomarker for the prediction and treatment of cancer.

Conclusion

FBXO31 is a unique and highly conserved protein that is involved in various cellular processes. Its structure and function make it a potential drug target and biomarker. The regulation of FBXO31 has been shown to be involved in the development and progression of various diseases, including cancer. Therefore, it is a promising target for small molecules and antibodies that can modulate its activity. Further research is needed to fully understand the role of FBXO31 in

Protein Name: F-box Protein 31

Functions: Component of some SCF (SKP1-cullin-F-box) protein ligase complex that plays a central role in G1 arrest following DNA damage. Specifically recognizes phosphorylated cyclin-D1 (CCND1), promoting its ubiquitination and degradation by the proteasome, resulting in G1 arrest. May act as a tumor suppressor

The "FBXO31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets